Clinical Trial Update: CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock [Phase 4]

View source ↗

Summary

This update covers the Phase 4 CAPITAL DOREMI 2 trial comparing an inotrope against placebo for cardiogenic shock, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Inotrope

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: Shock, Cardiogenic | Phase 4 | Status: RECRUITING